Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-969 |
| Synonyms | |
| Therapy Description |
ABBV-969 is an antibody-drug conjugate (ADC) comprising an antibody targeting PSMA and STEAP1 linked to a topoisomerase I inhibitor payload, which potentially induces tumor cell death (Ann Oncol 35 (2024): S1000-S1001, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-969 | ABBV 969|ABBV969 | PSMA Antibody 22 | ABBV-969 is an antibody-drug conjugate (ADC) comprising an antibody targeting PSMA and STEAP1 linked to a topoisomerase I inhibitor payload, which potentially induces tumor cell death (Ann Oncol 35 (2024): S1000-S1001, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06318273 | Phase I | ABBV-969 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ISR | FRA | ESP | CAN | AUS | 1 |